Peng, David H.
Rodriguez, Bertha Leticia
Diao, Lixia http://orcid.org/0000-0001-6995-4492
Chen, Limo
Wang, Jing http://orcid.org/0000-0002-5398-0802
Byers, Lauren A. http://orcid.org/0000-0002-0780-2677
Wei, Ying
Chapman, Harold A. http://orcid.org/0000-0002-5280-5527
Yamauchi, Mitsuo
Behrens, Carmen
Raso, Gabriela http://orcid.org/0000-0003-2105-5556
Soto, Luisa Maren Solis http://orcid.org/0000-0002-1253-630X
Cuentes, Edwin Roger Parra http://orcid.org/0000-0001-9068-1636
Wistuba, Ignacio I.
Kurie, Jonathan M.
Gibbons, Don L.
Article History
Received: 31 July 2019
Accepted: 12 August 2020
First Online: 9 September 2020
Competing interests
: D.L.G. declares advisory board/consulting work for Janssen, AstraZeneca, GlaxoSmithKline, Astellas, Ribon Therapeutics and Sanofi. D.L.G. receives research grant funding from AstraZeneca, Janssen, Ribon Therapeutics, Astellas and Takeda. L.A.B. declares consulting work for AstraZeneca, AbbVie, GenMab, BergenBio, Pharma Mar, SA. L.A.B. receives research grant funding from AbbVie, AstraZeneca, GenMab, Tolero Pharmaceuticals. All other authors declare that they have no conflict of interests.